<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0002">
 <label>Table 2</label>
 <caption>
  <p>Health Impacts and Maximum Cost-Effective LA-ART Administration Cost
   <xref rid="tb2fn1" ref-type="table-fn">a</xref>.
  </p>
 </caption>
 <alt-text id="alt0005">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top"/>
    <th valign="top">Base</th>
    <th valign="top">Lower Uptake</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top">Proportion of AYA on ART who switch to LA-ART
     <xref rid="tb2fn2" ref-type="table-fn">b</xref>
    </td>
    <td valign="top">85%</td>
    <td valign="top">71%
     <xref rid="tb2fn3" ref-type="table-fn">c</xref>
    </td>
   </tr>
   <tr>
    <td valign="top">Viral suppression of AYA on LA-ART
     <xref rid="tb2fn4" ref-type="table-fn">d</xref>
    </td>
    <td valign="top">94%</td>
    <td valign="top">94%</td>
   </tr>
   <tr>
    <td valign="top">Overall (oral and long-acting) viral suppression of AYA ART users</td>
    <td valign="top">91%</td>
    <td valign="top">78%</td>
   </tr>
   <tr>
    <td valign="top"/>
    <td valign="top"/>
    <td valign="top"/>
   </tr>
   <tr>
    <td valign="top">HIV infections averted (% of estimated new infections)</td>
    <td valign="top">40,540 (4•5%)</td>
    <td valign="top">6807 (0•8%)</td>
   </tr>
   <tr>
    <td valign="top">Deaths averted (% of all deaths)</td>
    <td valign="top">20,480 (0•9%)</td>
    <td valign="top">4178 (0•2%)</td>
   </tr>
   <tr>
    <td valign="top">DALYs averted</td>
    <td valign="top">122,081</td>
    <td valign="top">25,173</td>
   </tr>
   <tr>
    <td valign="top">Maximum incremental annual cost ($500 threshold)</td>
    <td valign="top">$89</td>
    <td valign="top">$20</td>
   </tr>
   <tr>
    <td valign="top">Maximum incremental annual cost ($1508 threshold)</td>
    <td valign="top">$236</td>
    <td valign="top">$56</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tb2fn1">
   <label>a</label>
   <p id="notep0003">Costs and health outcomes are captured over 10-year time horizon. Incremental costs and DALYs associated with each scenario are discounted at 3% annually. LA-ART intervention is added to current ART expansion. Costs are in 2017 USD.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tb2fn2">
   <label>b</label>
   <p id="notep0004">85% of AYA on ART desiring to switch to LA-ART based on LA-ART interest survey in U.S.
    <sup>21</sup>.
   </p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tb2fn3">
   <label>c</label>
   <p id="notep0005">30% of AYA who are not virally suppressed under oral ART, 85% who are suppressed under oral ART.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tb2fn4">
   <label>d</label>
   <p id="notep0006">94% viral suppression based on LATTE-2 phase 2b trial
    <sup>20</sup>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
